{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:31:57Z","timestamp":1777613517714,"version":"3.51.4"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Veterans Health Administration"},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clinical Sciences Research and Development"},{"DOI":"10.13039\/100009937","name":"Reed College","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009937","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"crossref","award":["1-F32-MH071137-01"],"award-info":[{"award-number":["1-F32-MH071137-01"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.neuropharm.2011.07.040","type":"journal-article","created":{"date-parts":[[2011,8,6]],"date-time":"2011-08-06T20:26:57Z","timestamp":1312662417000},"page":"313-321","source":"Crossref","is-referenced-by-count":7,"title":["Corticotropin releasing factor-1 receptor antagonism alters the biochemical, but not behavioral effects of repeated interleukin-1\u03b2 administration"],"prefix":"10.1016","volume":"62","author":[{"given":"Clare J.","family":"Wilhelm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Murphy-Crews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Menasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn S.","family":"Huckans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Loftis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2011.07.040_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1160\/TH08-07-0421","article-title":"Compensatory anti-inflammatory response syndrome","volume":"101","author":"Adib-Conquy","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib2","first-page":"4","article-title":"Cascading effects of stressors and inflammatory immune activation: implications for major depressive disorder","volume":"34","author":"Anisman","year":"2009","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/appi.ajp.2008.07071199","article-title":"A\u00a06-week randomized, placebo-controlled trial of CP-316-311 (a selective CRH1 antagonist) in the treatment of major depression","volume":"165","author":"Binneman","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib4","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/00006842-200207000-00010","article-title":"Fatigue and proinflammatory cytokine activity in breast cancer survivors","volume":"64","author":"Bower","year":"2002","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0893-133X(01)00407-9","article-title":"Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions","volume":"26","author":"Capuron","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbi.2003.11.004","article-title":"Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and\/or interferon-alpha cancer therapy","volume":"18","author":"Capuron","year":"2004","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0810as55","article-title":"Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice","author":"Castagn\u00e9","year":"2011","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0079-6123(10)82002-3","article-title":"Impact of the hypothalamic-pituitary-adrenal\/gonadal axes on trajectory of age-related cognitive decline","volume":"128","author":"Conrad","year":"2010","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0006-8993(91)91587-Q","article-title":"Behavioural effects of peripherally injected interleukin-1: role of prostaglandins","volume":"542","author":"Crestani","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0006-8993(91)90123-D","article-title":"Androgen-dependent vasopressinergic neurotransmission attenuates interleukin-1-induced sickness behavior","volume":"557","author":"Dantzer","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.psyneuen.2010.09.012","article-title":"Inflammation-associated depression: from serotonin to kynurenine","volume":"36","author":"Dantzer","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0006-8993(03)02485-5","article-title":"Exposure to forced swim stress does not alter central production of IL-1","volume":"972","author":"Deak","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbr.2004.11.024","article-title":"Behavioral responses during the forced swim test are not affected by anti-inflammatory agents or acute illness induced by lipopolysaccharide","volume":"160","author":"Deak","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0006-8993(90)90212-T","article-title":"Interleukin-1 affects the behavioral despair response in rats by an indirect mechanism which requires endogenous CRF","volume":"24","author":"del Cerro","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib16","doi-asserted-by":"crossref","first-page":"12280","DOI":"10.1074\/jbc.M111236200","article-title":"Corticotropin-releasing hormone induces Fas ligand production and apoptosis in PC12 cells via activation of p38 mitogen-activated protein kinase","volume":"277","author":"Dermitzaki","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","article-title":"A\u00a0meta-analysis of cytokines in major depression","volume":"67","author":"Dowlati","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib19","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.pbb.2005.04.019","article-title":"Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice","volume":"81","author":"Dunn","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1196\/annals.1410.022","article-title":"Effects of acute and chronic stressors and CRF in rat and mouse tests for depression","volume":"1148","author":"Dunn","year":"2008","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib21","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.bbi.2011.02.015","article-title":"Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue","volume":"25","author":"Felger","year":"2011","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1742-2094-7-43","article-title":"Central administration of lipopolysaccharide induces depressive-like behavior in\u00a0vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures","volume":"7","author":"Fu","year":"2010","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrrheum.2010.4","article-title":"IL-1 pathways in inflammation and human diseases","volume":"6","author":"Gabay","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1099800410379497","article-title":"Methodologic issues in the measurement of cytokines to elucidate the biological basis for cancer symptoms","volume":"13","author":"Gilbertson-White","year":"2011","journal-title":"Biol. Res. Nurs."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0885-3924(93)90127-H","article-title":"Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer","volume":"8","author":"Greenberg","year":"1993","journal-title":"J.\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib26","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.physbeh.2006.03.002","article-title":"Interleukin-10 (IL-10) but not lipopolysaccharide (LPS) produces increased motor activity and abnormal exploratory patterns while impairing spatial learning in Balb\/c mice","volume":"87","author":"Harvey","year":"2006","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib27","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1210\/endo.131.5.1425414","article-title":"Continuous infusion of interleukin-1 beta induces a nonthyroidal illness syndrome in the rat","volume":"131","author":"Hermus","year":"1992","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib28","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00213-004-2028-y","article-title":"Effects of CRF1 receptor antagonists and benzodiazepines in the Morris water maze and delayed non-matching to position tests","volume":"178","author":"Hogan","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/PSY.0b013e3181907c1b","article-title":"Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis","volume":"71","author":"Howren","year":"2009","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib30","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.neuroscience.2009.12.003","article-title":"Nitric oxide and interleukin-1beta mediate noradrenergic induced corticotrophin-releasing hormone release in organotypic cultures of rat paraventricular nucleus","volume":"165","author":"Hsieh","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1440-1819.2007.01686.x","article-title":"T-helper 1\/T-helper 2 cytokine imbalance and clinical phenotypes of acute-phase major depression","volume":"61","author":"Huang","year":"2007","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0006-291X(89)92422-4","article-title":"Local stimulation of prostaglandin production by corticotropin-releasing hormone in human fetal membranes and placenta","volume":"159","author":"Jones","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1507\/endocrj.K09E-075","article-title":"Regulatory mechanisms underlying corticotropin-releasing factor gene expression in the hypothalamus","volume":"56","author":"Kageyama","year":"2009","journal-title":"Endocr. J."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib34","doi-asserted-by":"crossref","first-page":"9117","DOI":"10.1073\/pnas.89.19.9117","article-title":"Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1","volume":"89","author":"Kent","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib35","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1111\/j.1460-9568.2008.06549.x","article-title":"Central nervous action of interleukin-1 mediates activation of limbic structures and behavioural depression in response to peripheral administration of bacterial lipopolysaccharide","volume":"28","author":"Konsman","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neulet.2010.08.054","article-title":"Serum anti-inflammatory markers in general population subjects with elevated depressive symptoms","volume":"484","author":"Lehto","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/jpet.103.058784","volume":"309","author":"Lelas","year":"2004","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib38","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.4088\/JCP.v67n1114","article-title":"Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy","volume":"67","author":"Leo","year":"2006","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/hup.1011","article-title":"The psychoneuroimmunology of depression","volume":"24","author":"Leonard","year":"2009","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2005.tb00034.x","article-title":"The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists","volume":"11","author":"Li","year":"2005","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib41","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2174\/1568026611109060609","article-title":"The role of corticotropin-releasing hormone in the pathophysiology of depression: therapeutic implications","volume":"11","author":"Lloyd","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jad.2004.04.002","article-title":"The phenomenology and treatment of interferon-induced depression","volume":"82","author":"Loftis","year":"2004","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.neulet.2007.11.001","article-title":"Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha","volume":"430","author":"Loftis","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib44","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1210\/endo.136.9.7544278","article-title":"CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues","volume":"136","author":"Lovenberg","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpsychires.2008.02.004","article-title":"IL-10 modulates depressive-like behavior","volume":"43","author":"Mesquita","year":"2008","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF02688853","article-title":"Cytokine-purine interactions in behavioral depression in rats","volume":"38","author":"Minor","year":"2003","journal-title":"Integr. Physiol. Behav. Sci."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib47","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.lfs.2005.06.003","article-title":"Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?","volume":"78","author":"Nielsen","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib48","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1210\/en.2010-0266","article-title":"Regulation of glucocorticoid receptor transcription and nuclear translocation during single and repeated immobilization stress","volume":"151","author":"Noguchi","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1034\/j.1600-0447.2001.00162.x","article-title":"Raised levels of plasma interleukin-1beta in major and postviral depression","volume":"103","author":"Owen","year":"2001","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib76","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0165-1781(03)00063-5","article-title":"Somatic symptoms in treatment-resistant depression","volume":"118","author":"Papakostas","year":"2003","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib50","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.0022-202X.2005.23656.x","article-title":"Corticotropin-releasing hormone (CRH) downregulates interleukin-18 expression in human HaCaT keratinocytes by activation of p38 mitogen-activated protein kinase (MAPK) pathway","volume":"124","author":"Park","year":"2005","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib51","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1146\/annurev.immunol.22.012703.104622","article-title":"Interleukin-10 and related cytokines and receptors","volume":"22","author":"Pestka","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib52","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/1535-7163.MCT-09-0186","article-title":"Targeting migration inducting gene-7 inhibits carcinoma cell invasion, early primary tumor growth and stimulates monocyte oncolytic activity","volume":"8","author":"Petty","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib53","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.neuroscience.2009.01.072","article-title":"Neurochemical and behavioral alterations in an inflammatory model of depression: sex differences exposed","volume":"159","author":"Pitychoutis","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib54","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1517\/13543784.2011.594039","article-title":"Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited","volume":"20","author":"Prins","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib55","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1159\/000126778","article-title":"Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients","volume":"60","author":"Raadsheer","year":"1994","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib56","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/00004647-199710000-00013","article-title":"Global forebrain ischemia results in differential cellular and expression of interleukin-1beta (IL-1beta) and its receptor at mRNA and protein level","volume":"17","author":"Sairanen","year":"1997","journal-title":"J.\u00a0Cereb. Blood Flow Metab."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib57","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0306-4530(00)00051-2","article-title":"Acute interferon-alpha administration modulates sucrose consumption in the rat","volume":"26","author":"Sammut","year":"2001","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib58","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1126\/science.2821621","article-title":"Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor","volume":"238","author":"Sapolsky","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib59","doi-asserted-by":"crossref","first-page":"e4324","DOI":"10.1371\/journal.pone.0004324","article-title":"The combined dexamethasone\/CRH Test (DEX\/CRF test) and prediction of acute treatment response in major depression","volume":"4","author":"Sch\u00fcle","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib60","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1677\/joe.0.1450201","article-title":"Glucocorticoid hypersecretion and the age-impaired hippocampus: cause or effect","volume":"145","author":"Seckl","year":"1995","journal-title":"J.\u00a0Endocrinol."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib61","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.euroneuro.2007.06.004","article-title":"A\u00a0detailed examination of cytokine abnormalities in Major Depressive Disorder","volume":"18","author":"Simon","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib62","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1055\/s-2006-941557","article-title":"The comparison of changes in behavior, neurochemistry, endocrine, and immune functions after different routes, doses, and durations of administrations of IL-1 beta in rats","volume":"39","author":"Song","year":"2006","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib63","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nri1810","article-title":"Neural response of innate immunity: a coordinated nonspecific host response to pathogens","volume":"6","author":"Sternberg","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib64","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0006-8993(88)90868-2","article-title":"Interleukin-1 induces conditioned taste aversion in rats: a possible explanation for its pituitary-adrenal stimulating activity","volume":"473","author":"Tazi","year":"1988","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib65","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/sj.npp.1301488","article-title":"Intranasal immune challenge induces sex-dependent depressive-like behavior and cytokine expression in the brain","volume":"33","author":"Tonelli","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib66","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2165\/00023210-200620110-00002","article-title":"Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date","volume":"20","author":"Valdez","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib67","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2174\/138161209788168083","article-title":"CRF receptors as a potential target in the development of novel pharmacotherapies for depression","volume":"15","author":"Valdez","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib68","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/378287a0","article-title":"Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor","volume":"378","author":"Vaughan","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib69","doi-asserted-by":"crossref","first-page":"R1401","DOI":"10.1152\/ajpregu.2001.281.5.R1401","article-title":"Peripheral urocortin inhibits gastric emptying and food intake in mice: differential role of CRF receptor 2","volume":"281","author":"Wang","year":"2001","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib70","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s001099900051","article-title":"Mechanisms of brain-mediated systemic anti-inflammatory syndrome causing immunodepression","volume":"77","author":"Woiciechowsky","year":"1999","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib71","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1188\/06.ONF.535-542","article-title":"Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines","volume":"33","author":"Wood","year":"2006","journal-title":"Oncol. Nurs. Forum"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib72","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1099800406290932","article-title":"The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms","volume":"8","author":"Wood","year":"2006","journal-title":"Biol. Res. Nurs."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib73","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1038\/npp.2010.116","article-title":"Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters","volume":"35","author":"Zhu","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2011.07.040_bib74","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0022-3956(00)00016-9","article-title":"Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated","volume":"34","author":"Zobel","year":"2000","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2011.07.040_bib75","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.drudis.2010.02.011","article-title":"Progress in corticotropin-releasing factor-1 antagonist development","volume":"15","author":"Zorrilla","year":"2010","journal-title":"Drug Discov. Today"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390811003285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390811003285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T17:28:56Z","timestamp":1712683736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390811003285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0028390811003285"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2011.07.040","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}